Looking for an Investment Guru? Try the Walrus

Alan Stevens |

Paul_McCartney_Dublin_2010.jpgWho is my pick for a great value investor to emulate? Sir Paul McCartney.

I know, I know, I’m supposed to respond with Ben Graham or maybe Warren Buffett, but McCartney is a great example of how to be successful through value investing, and one whose approach is far more accessible to the average investor - anyone can apply Paul McCartney’s lessons for investing success (and no, step one is not, “launch one of the biggest bands in the world.”).

So how did he do it? Paul found initial success while still in his early twenties as a member of the Beatles. Other members of the band were buying Rolls Royce limousines and acquiring financial advisors, but Paul told NPR in an interview that he knew nothing about stocks, bonds or real estate. He was wary of placing his newfound money with intermediaries who wanted him to invest in things he didn’t understand.

It was about that time that he heard about a small music publisher for sale, and suddenly a light came on for the young songwriter. He might not know about stocks or bonds, but he knew about music and what made a song marketable. He felt comfortable valuing a catalogue of songs and music rights. Confident in his expertise, he bought the publisher and spent the next four decades reinvesting his earnings and amassing one of the world’s great collections of songs and music rights on the planet.

Baby, You're a Rich Man

Today MPL Communications (McCartney Productions Limited) boasts a catalogue of over 25,000 songs and the publishing rights to productions like Annie, A Chorus Line, Guys and Dolls and Grease. Just one song, Wonderful Christmastime, earns him almost as much in royalties each year as the entire Beatles catalogue combined.  

Paul became rich through his association with The Beatles, but he became one of the world’s wealthiest men by focusing his investments within his expertise – where he had the confidence to act boldly. That’s all value investing is: figuring out what something is worth and then paying substantially less. It’s a lot easier to do when you understand the thing you are trying to value. This is the story I tell people whenever they ask my view on a biotech stock whose name they can hardly pronounce.



Alan Stevens is Managing Director of Research and Portfolio Management at Lyons Wealth Management LLC, a Florida-based subadvisor to several mutual funds. He serves as Portfolio Manager for Catalyst/Lyons Tactical Allocation Fund and is Co-Portfolio Manager for Catalyst/Lyons Hedged Premium Return Fund. He also manages several separate managed account strategies and alternative asset funds, including Lyons Tactical Overlay Program. He holds his MBA from Harvard Business School and a BA from Lake Forest College.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Reliq Health Technologies Inc.

Moseda Technologies Inc provides mobile and IT cloud computing to increase operational efficiency and security. It develops SmartFleet, a solution designed for commercial use, as well as SmartCare, a mHealth…

Private Markets


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…